Corient Private Wealth LLC raised its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 447.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,338 shares of the company's stock after acquiring an additional 128,590 shares during the period. Corient Private Wealth LLC's holdings in Dr. Reddy's Laboratories were worth $2,484,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after acquiring an additional 9,373,412 shares during the period. Fisher Asset Management LLC raised its position in Dr. Reddy's Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock valued at $38,981,000 after purchasing an additional 1,977,419 shares in the last quarter. State Street Corp lifted its stake in Dr. Reddy's Laboratories by 1.9% during the third quarter. State Street Corp now owns 909,905 shares of the company's stock worth $72,292,000 after purchasing an additional 16,641 shares during the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of Dr. Reddy's Laboratories by 356.7% in the 4th quarter. Mondrian Investment Partners LTD now owns 648,813 shares of the company's stock valued at $10,245,000 after purchasing an additional 506,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Dr. Reddy's Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after purchasing an additional 427,573 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the stock. StockNews.com cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.
Read Our Latest Stock Report on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Trading Down 0.1 %
RDY stock traded down $0.01 during trading on Thursday, hitting $13.28. The company had a trading volume of 3,053,379 shares, compared to its average volume of 1,289,275. The stock has a market cap of $11.08 billion, a PE ratio of 21.14 and a beta of 0.48. The business has a 50-day moving average of $13.55 and a 200-day moving average of $14.64. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a one year low of $12.50 and a one year high of $16.89.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
